Gene Therapy for Blood Disorders

Revolutionary gene therapies are redefining the treatment of blood diseases.

With an approved gene therapy treatment for β-thalassemia in the EU, and hemophilia candidates seeking 2020 approval in the USA and beyond, pioneers in the space must overcome hurdles they have never previously encountered to transform their clinical candidates into a commercial reality. Gene Therapy for Blood Disorders will unite industry leaders across the blood disease space to delve into the specific clinical and commercial challenges faced by companies developing gene therapies for hemophilia, sickle cell disease and β-thalassemia.

Evaluate the best strategies for a commercial launch in blood disease, optimize your trial design, gain insights on revolutionary novel technologies, and ultimately enhance your current hematology gene therapy program to bring transformative treatments to patients more quickly and efficiently.

URLs:
Tickets: https://go.evvnt.com/552809-1?pid=5248
Brochure: https://go.evvnt.com/552809-3?pid=5248

Prices:
Conference Only Industry - Early Rate: USD 2299.00
Conference Only Industry - Standard Rate: USD 2899.00
Conference Only Academic - Early Rate: USD 1899.00
Conference Only Academic - Standard Rate: USD 2499.00

Speakers: Grant Blouse Catalyst Biosciences, Julianne Bruno CRISPR Therapeutics, John Chapin CRISPR Therapeutics, Colleen Dansereau Boston Children’s Hospital, Mrudula Donepudi Editas Medicine, Catalina Driscoll Sanofi Genzyme, Dean Falb LogicBio, Meghan Gallagher bluebird bio, Nicolas Garnier Pfizer Rare Disease, Angela Johnson Sigilon Therapeutics, Paul Monahan Spark Therapeutics, Dawn Rotellini National Hemophilia Foundation, Eileen Sawyer uniQure, Julian Down Poseida Therapeutics, Matt Trudeau bluebird bio, Sander van Deventer uniQure, John Woolley University of Liverpool

Category: Conferences / Science, Health and Medicine / Pharmaceuticals

Sesh by The Boston Calendar | Advertise Terms | Privacy Policy | About